View Filing Data

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2013 USD ($) shares
Document and Entity Information [Abstract]
Entity Registrant Name	Emergent BioSolutions Inc.
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float \| $	$ 0
Entity Common Stock, Shares Outstanding \| shares	36,121,353
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2013

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 130,238	$ 141,666
Accounts receivable	62,964	96,043
Inventories	22,148	15,161
Deferred tax assets, net	1,264	1,264
Income tax receivable, net	10,762	0
Prepaid expenses and other current assets	9,703	9,213
Total current assets	237,079	263,347
Property, plant and equipment, net	242,344	241,764
In-process research and development	41,800	41,800
Goodwill	5,502	5,502
Deferred tax assets, net	11,087	11,087
Other assets	573	730
Total assets	538,385	564,230
Current liabilities:
Accounts payable	23,871	31,297
Accrued expenses and other current liabilities	1,517	1,603
Accrued compensation	11,675	22,726
Long-term indebtedness, current portion	4,470	4,470
Deferred revenue	2,008	1,811
Total current liabilities	43,541	61,907
Long-term indebtedness, net of current portion	57,187	58,304
Other liabilities	1,852	1,891
Total liabilities	102,580	122,102
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 36,521,011 shares issued and 36,117,853 shares outstanding at March 31, 2013; 36,272,550 shares issued and 35,869,392 shares outstanding at December 31, 2012	36	36
Additional paid-in capital	232,887	230,964
Treasury stock, at cost, 403,158 common shares at March 31, 2013 and December 31, 2012	(5,906)	(5,906)
Accumulated other comprehensive loss	(3,759)	(4,129)
Retained earnings	212,330	220,393
Total Emergent BioSolutions Inc. stockholders' equity	435,588	441,358
Noncontrolling interest in subsidiaries	217	770
Total stockholders' equity	435,805	442,128
Total liabilities and stockholders' equity	$ 538,385	$ 564,230

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2013	Dec. 31, 2012
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	36,521,011	36,272,550
Common stock, shares outstanding (in shares)	36,117,853	35,869,392
Treasury Stock ( in Shares)	403,158	403,158

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues:
Product sales	$ 30,359	$ 34,357
Contracts and grants	12,741	15,954
Total revenues	43,100	50,311
Operating expenses:
Cost of product sales	5,698	7,511
Research and development	30,724	26,246
Selling, general and administrative	20,028	19,492
Impairment of in-process research and development	0	9,600
Loss from operations	(13,350)	(12,538)
Other income (expense):
Interest income	23	25
Interest expense	(11)	(3)
Other income (expense), net	17	854
Total other income (expense)	29	876
Loss before benefit from income taxes	(13,321)	(11,662)
Benefit from income taxes	(4,516)	(3,640)
Net loss	(8,805)	(8,022)
Net loss attributable to noncontrolling interest	743	1,193
Net loss attributable to Emergent BioSolutions Inc.	$ (8,062)	$ (6,829)
Loss per share - basic	$ (0.22)	$ (0.19)
Loss per share - diluted	$ (0.22)	$ (0.19)
Weighted-average number of shares - basic	35,968,064	36,045,839
Weighted-average number of shares - diluted	35,968,064	36,045,839

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Consolidated Statements of Comprehensive Loss (unaudited) [Abstract]
Net loss attributable to Emergent BioSolutions Inc.	$ (8,062)	$ (6,829)
Foreign currency translations, net of tax	370	84
Comprehensive loss	$ (7,692)	$ (6,745)

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the economic entity, including both controlling (parent) and noncontrolling interests. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, including any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (8,805)	$ (8,022)
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	2,976	2,712
Depreciation and amortization	4,163	2,373
Current and deferred income taxes	(4,516)	6,944
Non-cash development expenses from joint venture	190	1,212
Impairment of in-process research and development	0	9,600
Change in fair value of contingent value rights	0	(3,005)
Excess tax benefits from stock-based compensation	(1,608)	(1,118)
Other	6	(19)
Changes in operating assets and liabilities:
Accounts receivable	33,079	30,501
Inventories	(6,987)	(2,658)
Income taxes	(7,918)	(11,154)
Prepaid expenses and other assets	(246)	443
Accounts payable	(4,196)	(1,988)
Accrued expenses and other liabilities	21	(11)
Accrued compensation	(10,982)	(10,895)
Deferred revenue	197	(1,075)
Net cash provided by (used in) operating activities	(4,626)	13,840
Cash flows from investing activities:
Purchases of property, plant and equipment	(7,679)	(22,329)
Proceeds from sale of assets	0	11,765
Proceeds from maturity of investments	0	1,966
Net cash used in investing activities	(7,679)	(8,598)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	0	9,621
Issuance of common stock subject to exercise of stock options	504	242
Excess tax benefits from stock-based compensation	1,608	1,118
Principal payments on long-term indebtedness	(1,117)	(8,203)
Contingent value right payment	0	(1,748)
Restricted cash	0	220
Net cash provided by financing activities	995	1,250
Effect of exchange rate changes on cash and cash equivalents	(118)	32
Net increase (decrease) in cash and cash equivalents	(11,428)	6,524
Cash and cash equivalents at beginning of period	141,666	143,901
Cash and cash equivalents at end of period	$ 130,238	$ 150,425

Basis of presentation and consolidation

3 Months Ended

Mar. 31, 2013

Basis of presentation and consolidation

Basis of presentation and consolidation

1.	Basis of presentation and consolidation

The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.

In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of March 31, 2013 and the results of operations, comprehensive loss and cash flows for the three months ended March 31, 2013 and 2012. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.

Fair value measurements

3 Months Ended

Mar. 31, 2013

Fair value measurements [Abstract]

Fair value measurements

2. Fair value measurements

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At March 31, 2013
(in thousands)	Level 1			Level 2			Level 3			Total
Assets:
Investment in money market funds (1)		$	31,562		$	-		$	-		$	31,562
Total assets		$	31,562		$	-		$	-		$	31,562


	At December 31, 2012
(in thousands)	Level 1			Level 2			Level 3			Total
Assets:
Investment in money market funds (1)		$	42,720		$	-		$	-		$	42,720
Total assets		$	42,720		$	-		$	-		$	42,720

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

As of March 31, 2013 and December 31, 2012, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.

The fair value of the contingent value right ("CVR") obligations is based on management's assessment of certain development and collaboration milestones, which are inputs that have no observable market (Level 3). The obligation is measured using a discounted cash flow model. For the three months ended March 31, 2012, the Company recorded a decrease in the CVR obligations of $3.0 million due to Pfizer ceasing development of programs related to the CVR milestones and made a $1.7 million CVR payment under the Company's agreement with Abbott. The adjustments to fair value are classified in the Company's statement of operations as research and development expense within the Company's Biosciences segment.

As of March 31, 2013 and December 31, 2012, the Company had no assets or liabilities measured at fair value using significant unobservable inputs (Level 3).

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. For the three months ended March 31, 2013, no assets or liabilities were measured at fair value on a nonrecurring basis. For the year ended December 31, 2012, the Company's SBI-087 in-process research and development ("IPR&D") asset, which was categorized as a level 3 fair value measurement, was the only asset or liability measured at fair value on a nonrecurring basis (see Note 4).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventories

3 Months Ended

Mar. 31, 2013

Inventories [Abstract]

Inventories

3. Inventories

Inventories consist of the following:

	March 31,		December 31,
(in thousands)	2013		2012
Raw materials and supplies	$	2,565	$	2,733
Work-in-process		17,080		9,813
Finished goods		2,503		2,615
Total inventories	$	22,148	$	15,161

In-process research and development and goodwill	3 Months Ended
In-process research and development and goodwill	Mar. 31, 2013
In-process research and development and goodwill [Abstract]
In-process research and development and goodwill	4. In-process research and development and goodwill During the three months ended March 31, 2012, Pfizer terminated its development programs with respect to the Company's SBI-087 product candidate. The Company considered this termination a potential indicator of impairment of the related SBI-087 IPR&D asset, and assessed the fair value of this asset. As part of the assessment, the Company considered the impact of Pfizer's decision, along with the Company's decision to no longer pursue further development of this asset due to reduced overall probability of success and increased development costs for the product candidate. As a result, the Company recorded an impairment charge of $9.6 million during the three months ended March 31, 2012, which represented the entire carrying value of the SBI-087 IPR&D asset. This charge is classified in the Company's statement of operations as impairment of in-process research and development, within the Company's Biosciences segment. As a result of the impairment of the SBI-087 IPR&D asset, the Company also performed an analysis of the Biosciences therapeutic reporting unit, which contains all goodwill reported on the Company's consolidated balance sheets for the period ended March 31, 2012. Based on the analysis, the Company concluded that goodwill was not more likely than not impaired and therefore an interim impairment analysis was deemed unnecessary.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Stockholders' equity

3 Months Ended

Mar. 31, 2013

Stockholders' equity [Abstract]

Stockholders' equity

5. Equity awards

The following is a summary of stock option award activity under the Second Amended and Restated Emergent BioSolutions Inc., 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan"):

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		3,550,842		$	17.07		53,156	$	8.86	$	4,801,378
Granted		812,910			14.67		-		-
Exercised		(56,499	)		8.91		-		-
Forfeited		(127,786	)		18.55		-		-
Outstanding at March 31, 2013		4,179,467		$	16.67		53,156	$	8.86	$	2,848,569
Exercisable at March 31, 2013		2,575,695		$	16.86		53,156	$	8.86	$	2,848,569

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		715,609		$	18.41	$	11,478,368
Granted		406,454			14.67
Vested		(291,619	)		14.77
Forfeited		(15,848	)		17.16
Outstanding at March 31, 2013		814,596		$	16.46	$	5,737,280

During the three months ended March 31, 2013, the Company corrected an immaterial prior period error for the three months ended March 31, 2012 of approximately $2.0 million. This immaterial error related to the cash flow presentation of the excess tax benefit attributed to the exercise of non-qualified stock options and restricted stock units. The immaterial error had no impact on the Company's consolidated cash flows, consolidated statements of operations and comprehensive loss or the consolidated balance sheets. The correction of the error is reflected as a reduction of originally reported operating cash flow from operating activities and an increase in originally reported cash flow from financing activities.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Variable interest entities

3 Months Ended

Mar. 31, 2013

Variable interest entities [Abstract]

Variable interest entities

6. Variable interest entities

In July 2008, the Company entered into a collaboration with the University of Oxford ("Oxford") and certain Oxford researchers to advance a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). The Company has a 51% equity interest in OETC and controls the OETC Board of Directors. In addition, the Company had certain funding and service obligations related to its investment. In February 2013, the Company published clinical trial data which showed its tuberculosis vaccine product candidate did not confer statistically significant protection for the tuberculosis disease or infection in infants from those vaccinated at birth with the Baccile Calmette-Guerin vaccine. As a result of this clinical trial data, the Company is ceasing development work on this product candidate and expects future funding of OETC to be minimal.

The Company evaluates its variable interests in OETC on a quarterly basis and has determined that it is the primary beneficiary as it has the power to direct the activities of OETC that most significantly impact OETC's economic performance and will absorb the majority of expected losses. Accordingly, the Company consolidates OETC. As of March 31, 2013 and 2012, respectively, assets of $1.3 million and $506,000 and liabilities of $950,000 and $1.8 million related to OETC were included within the Company's consolidated balance sheets. During the three months ended March 31, 2013, OETC incurred net losses of $1.5 million of which $771,000 is included in the Company's consolidated statement of operations. During the three months ended March 31, 2012, OETC incurred net losses of $2.4 million, of which $1.2 million is included in the Company's consolidated statement of operations.

In conjunction with the establishment of OETC, the Company granted a put option to Oxford and certain Oxford researchers whereby the Company may be required to acquire all of the OETC shares held by Oxford and the Oxford researchers at the fair market value of the underlying shares. This put option is contingent upon the satisfaction of a number of conditions that must exist or occur subsequent to the granting by the European Commission of marketing authorization for the OETC-sponsored tuberculosis vaccine product candidate. The Company accounts for the put option in accordance with the accounting provisions related to derivatives and distinguishing liabilities from equity. In accordance with these provisions, the Company has determined that the put option had no value as of December 31, 2012 and March 31, 2013.

The following is a summary of the stockholders' equity attributable to the Company and the noncontrolling interests:

	Emergent			Noncontrolling
(in thousands)	BioSolutions Inc.			Interests			Total
Stockholders' equity at December 31, 2012	$	441,358		$	770		$	442,128
Non-cash development expenses from variable interest entities		-			190			190
Net loss		(8,062	)		(743	)		(8,805	)
Other		2,292			-			-
Stockholders' equity at March 31, 2013	$	435,588		$	217		$	435,805

- Definition

The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.

+ References + Details

Collaboration Agreements	3 Months Ended
Collaboration Agreements	Mar. 31, 2013
Collaboration Agreements [Abstract]
Collaboration Agreements	7. Collaboration agreements Abbott Laboratories In August 2009, Trubion Pharmaceuticals, Inc. ("Trubion"), which the Company acquired in October 2010, entered into a collaboration agreement with Facet Biotech Corporation, now a wholly-owned subsidiary of Abbott Laboratories ("Abbott"), for the joint worldwide development and commercialization of TRU-016. The collaboration agreement was terminated on March 20, 2012 and all rights to TRU-016 and other CD37-directed protein therapeutics under the collaboration agreement reverted back to the Company. During the three months ended March 31, 2012, the Company recorded revenue of $1.4 million for collaborative research and development services pursuant to the Abbott agreement, which is included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment. Pfizer Inc. In December 2005, Trubion entered into an agreement (the "Pfizer Agreement") with Wyeth Pharmaceuticals, now a wholly-owned subsidiary of Pfizer, for the development and worldwide commercialization of CD20-directed therapeutics. In September 2012, the Pfizer Agreement was terminated. In May 2011, the Company and Pfizer entered into a third amendment to the Pfizer Agreement (the "Biosimilar Amendment") in which the Company released certain restrictions related to the development and commercialization of biosimilar CD20 antibodies. Under the terms of this amendment, the Company is entitled to receive royalty payments in the low-single digits on net sales of certain Pfizer biosimilar products directed to CD20, subject to the satisfaction of specified conditions. The Company's right to receive royalty payments under the Biosimilar Amendment survives termination of the Pfizer Agreement. During the three months ended March 31, 2012, the Company recorded revenue of $365,000 for research and development services pursuant to the Pfizer agreement, which is included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment.

Restructuring

3 Months Ended

Mar. 31, 2013

Restructuring [Abstract]

Restructuring

8. Restructuring

In February 2013, the Company adopted a plan to restructure the operations of Emergent Product Development UK Limited ("EPDU") and OETC. The key driver for this restructuring was the reprioritization of the Company's product development portfolio.

The Company has made estimates and judgments regarding the amount and timing of this restructuring expense and liability, including current and future period termination benefits and other exit costs to be incurred when related actions take place. Severance and other related costs and asset-related charges are reflected within the Company's consolidated statement of income as a component of selling, general and administrative expense. Actual results may differ from these estimates.

The restructuring plan includes a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of leasehold improvements and equipment. The Company expects to complete this restructuring in 2013, and estimates that the total cost of the restructuring will be approximately $2.8 million. These estimated costs are detailed below:

	Incurred as of March 31,		Total Expected
(in thousands)	2013		to be Incurred
Termination benefits	$	1,840	$	1,904
Contract termination costs		-		500
Other costs		181		381
Total	$	2,021	$	2,785

The Company incurred $2.0 million in restructuring charges during the three months ended March 31, 2013, which is included in selling, general and administrative expense in its statement of operations and is included within the Biosciences segment.

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

			Lease
	Termination		Termination
(in thousands)	Benefits		Costs		Total
Balance at December 31, 2012	$	-	$	-	$	-
Expenses incurred		1,840		-		1,840
Amount paid		-		-		-
Other adjustments		-		-		-
Balance at March 31, 2013	$	1,840	$	-	$	1,840

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details

Business Interruption Insurance Recovery	3 Months Ended
Business Interruption Insurance Recovery	Mar. 31, 2013
Business Interruption Insurance Recovery [Abstract]
Business Interruption Insurance Recovery [Text Block]	9. Business interruption insurance recovery During the three months ended March 31, 2012, the Company recorded $835,000 in insurance recovery related to a power outage at its Lansing, Michigan facility. The insurance recovery is classified in the Company's statement of operations as other income (expense), net.

Earnings per share

3 Months Ended

Mar. 31, 2013

Earnings per share [Abstract]

Earnings per share

10. Earnings per share

The following table presents the calculation of basic and diluted net loss per share:

	Three Months Ended March 31,
(in thousands, except share and per share data)	2013			2012
Numerator:
Net loss	$	(8,062	)	$	(6,829	)

Denominator:
Weighted-average number of shares—basic		35,968,064			36,045,839
Dilutive securities—equity awards		-			-
Weighted-average number of shares—diluted		35,968,064			36,045,839

Loss per share-basic	$	(0.22	)	$	(0.19	)
Loss per share-diluted	$	(0.22	)	$	(0.19	)

Stock options with exercise prices in excess of the average per share closing price during the period are not considered in the calculation of fully diluted earnings per share. For the three month periods ended March 31, 2013 and 2012, approximately 5.0 million and 4.5 million stock options, respectively, were excluded from the calculation of diluted earnings per share because the net loss attributable to Emergent BioSolutions Inc. would make these awards antidilutive.

Segment information

3 Months Ended

Mar. 31, 2013

Segment information [Abstract]

Segment information

11. Segment information

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or operating divisions, engage in business activities for which discrete financial information is reviewed by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are composed of business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products and product candidates with different development processes.

The Biodefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets oncology indications, and consists of two business units, therapeutics and vaccines. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences.

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Three Months Ended March 31, 2013
External revenue	$	42,159		941			-			43,100
Net income (loss)		4,610		(11,372	)		(1,300	)		(8,062	)
Three Months Ended March 31, 2012
External revenue	$	48,636	$	1,675		$	-		$	50,311
Net income (loss)		14,266		(19,891	)		(1,204	)		(6,829	)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	12. Subsequent events In April 2013, the Company entered into an asset purchase agreement to acquire the Healthcare Protective Products Division of Bracco Diagnostics Inc. for $26.0 million in cash, plus contingent payments based on sales and development milestones. The transaction is expected to close in the third quarter of 2013.

Fair value measurements (Tables)

3 Months Ended

Mar. 31, 2013

Fair value measurements [Abstract]

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At March 31, 2013
(in thousands)	Level 1			Level 2			Level 3			Total
Assets:
Investment in money market funds (1)		$	31,562		$	-		$	-		$	31,562
Total assets		$	31,562		$	-		$	-		$	31,562


	At December 31, 2012
(in thousands)	Level 1			Level 2			Level 3			Total
Assets:
Investment in money market funds (1)		$	42,720		$	-		$	-		$	42,720
Total assets		$	42,720		$	-		$	-		$	42,720

Inventories (Tables)

3 Months Ended

Mar. 31, 2013

Inventories [Abstract]

Inventories

Inventories consist of the following:

	March 31,		December 31,
(in thousands)	2013		2012
Raw materials and supplies	$	2,565	$	2,733
Work-in-process		17,080		9,813
Finished goods		2,503		2,615
Total inventories	$	22,148	$	15,161

Stockholders' equity (Tables)

3 Months Ended

Mar. 31, 2013

Stockholders' equity [Abstract]

Option award activity

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		3,550,842		$	17.07		53,156	$	8.86	$	4,801,378
Granted		812,910			14.67		-		-
Exercised		(56,499	)		8.91		-		-
Forfeited		(127,786	)		18.55		-		-
Outstanding at March 31, 2013		4,179,467		$	16.67		53,156	$	8.86	$	2,848,569
Exercisable at March 31, 2013		2,575,695		$	16.86		53,156	$	8.86	$	2,848,569

Restricted stock units activity

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		715,609		$	18.41	$	11,478,368
Granted		406,454			14.67
Vested		(291,619	)		14.77
Forfeited		(15,848	)		17.16
Outstanding at March 31, 2013		814,596		$	16.46	$	5,737,280

Variable interest entities (Tables)

3 Months Ended

Mar. 31, 2013

Variable interest entities [Abstract]

Schedule of Variable Interest Entities [Table Text Block]

The following is a summary of the stockholders' equity attributable to the Company and the noncontrolling interests:

	Emergent			Noncontrolling
(in thousands)	BioSolutions Inc.			Interests			Total
Stockholders' equity at December 31, 2012	$	441,358		$	770		$	442,128
Non-cash development expenses from variable interest entities		-			190			190
Net loss		(8,062	)		(743	)		(8,805	)
Other		2,292			-			-
Stockholders' equity at March 31, 2013	$	435,588		$	217		$	435,805

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7880789&loc=d3e5747-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228884-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7880789&loc=d3e5728-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Variable Interest Entity
-URI http://asc.fasb.org/extlink&oid=6528138

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7880789&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6759159-111685

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 140
-Paragraph 35
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 2, 14, 15, 16, 23, 24, 25, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 167
-Paragraph 24
-Appendix D

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph C4
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 167
-Paragraph 22B
-Appendix D

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 167
-Paragraph 23A
-Appendix D

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 167
-Paragraph 22E
-Appendix D

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4
-Subparagraph g
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Restructuring (Tables)

3 Months Ended

Mar. 31, 2013

Restructuring [Abstract]

Costs of the restructuring

The restructuring plan includes a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of equipment. The Company expects to complete this restructuring in 2013, and estimates that the total cost of the restructuring will be approximately $2.8 million. These estimated costs are detailed below:

	Incurred as of March 31,		Total Expected
(in thousands)	2013		to be Incurred
Termination benefits	$	1,840	$	1,904
Contract termination costs		-		500
Other costs		181		381
Total	$	2,021	$	2,785

Summary of the activity for liabilities related to EPDU restructuring

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

			Lease
	Termination		Termination
(in thousands)	Benefits		Costs		Total
Balance at December 31, 2012	$	-	$	-	$	-
Expenses incurred		1,840		-		1,840
Amount paid		-		-		-
Other adjustments		-		-		-
Balance at March 31, 2013	$	1,840	$	-	$	1,840

Earnings per share (Tables)

3 Months Ended

Mar. 31, 2013

Earnings per share [Abstract]

Summary of basic and diluted net income per share

The following table presents the calculation of basic and diluted net loss per share:

	Three Months Ended March 31,
(in thousands, except share and per share data)	2013			2012
Numerator:
Net loss	$	(8,062	)	$	(6,829	)

Denominator:
Weighted-average number of shares—basic		35,968,064			36,045,839
Dilutive securities—equity awards		-			-
Weighted-average number of shares—diluted		35,968,064			36,045,839

Loss per share-basic	$	(0.22	)	$	(0.19	)
Loss per share-diluted	$	(0.22	)	$	(0.19	)

Segment information (Tables)

3 Months Ended

Mar. 31, 2013

Segment information [Abstract]

Segment information

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Three Months Ended March 31, 2013
External revenue	$	42,159		941			-			43,100
Net income (loss)		4,610		(11,372	)		(1,300	)		(8,062	)
Three Months Ended March 31, 2012
External revenue	$	48,636	$	1,675		$	-		$	50,311
Net income (loss)		14,266		(19,891	)		(1,204	)		(6,829	)

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Fair value measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2013	Dec. 31, 2012
Liabilities:
Contingent value rights	$ 1,700
Fair Value, Measurements, Recurring [Member]
Assets:
Investment in money market funds	31,562	$ 42,720
Total assets	31,562	42,720
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Investment in money market funds	31,562	42,720
Total assets	31,562	42,720
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Investment in money market funds	0	0
Total assets	0	0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets:
Investment in money market funds	0	0
Total assets	$ 0	$ 0

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2013	Dec. 31, 2012
Inventories [Abstract]
Raw materials and supplies	$ 2,565	$ 2,733
Work-in-process	17,080	9,813
Finished goods	2,503	2,615
Total inventories	$ 22,148	$ 15,161

In-process research and development and goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2013 USD ($)
In-process research and development and goodwill [Abstract]
Impairment of IPR&D assets	$ 9.6

Stockholders' equity (Details) - USD ($)	3 Months Ended
Stockholders' equity (Details) - USD ($)	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Preferred stock
Preferred stock, shares authorized (in shares)	15,000,000		15,000,000
Preferred stock, par value (in dollars per share)	$ 0.001		$ 0.001
Common stock
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001
Common stock, shares authorized (in shares)	100,000,000		100,000,000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,976,000	$ 2,712,000
Stock Options [Member]
Aggregate Intrinsic Value [Abstract]
Outstanding, beginning of period	4,801,378
Outstanding, end of period	2,848,569
Exercisable, end of period	$ 2,848,569
Restricted Stock Units (RSUs) [Member]
Restricted stock unit award activity [Roll Forward]
Outstanding, beginning of period (in shares)	715,609
Granted (in shares)	406,454
Vested (in shares)	(291,619)
Forfeited (in shares)	(15,848)
Outstanding, end of period (in shares)	814,596
Weighted-Average Grant Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 18.41
Granted (in dollars per share)	14.67
Vested (in dollars per share)	14.77
Forfeited (in dollars per share)	17.16
Outstanding, end of period (in dollars per share)	$ 16.46
Aggregate intrinsic value [Abstract]
Outstanding, beginning of period	$ 11,478,368
Outstanding, end of period	$ 5,737,280
2006 Plan [Member] \| Stock Options [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	3,550,842
Granted (in shares)	812,910
Exercised (in shares)	(56,499)
Forfeited (in shares)	(127,786)
Outstanding, end of period (in shares)	4,179,467
Exercisable, end of period (in shares)	2,575,695
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 17.07
Granted (in dollars per share)	14.67
Exercised (in dollars per share)	8.91
Forfeited (in dollars per share)	18.55
Outstanding, end of period (in dollars per share)	16.67
Exercisable, end of period (in dollars per share)	$ 16.86
2004 Plan [Member] \| Stock Options [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	53,156
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding, end of period (in shares)	53,156
Exercisable, end of period (in shares)	53,156
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 8.86
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	0
Outstanding, end of period (in dollars per share)	8.86
Exercisable, end of period (in dollars per share)	$ 8.86

Variable interest entities (Details) - USD ($)	3 Months Ended
Variable interest entities (Details) - USD ($)	Mar. 31, 2013	Mar. 31, 2012
Variable Interest Entity [Line Items]
Net loss	$ (8,805,000)	$ (8,022,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity beginning of period	442,128,000
Non-cash development expenses from variable interest entities	190,000
Net Loss	(8,805,000)	(8,022,000)
Other	0
Stockholders' equity end of period	435,805,000
Oxford-Emergent Tuberculosis Consortium [Member]
Variable Interest Entity [Line Items]
Assets	1,300,000	506,000
Liabilities	950,000	1,800,000
Net loss	1,500,000	2,400,000
Net losses included in the Company's consolidated statement of operations	771,000	1,200,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Loss	1,500,000	$ 2,400,000
Emergent BioSolutions Inc. [Member]
Variable Interest Entity [Line Items]
Net loss	(8,062,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity beginning of period	441,358,000
Non-cash development expenses from variable interest entities	0
Net Loss	(8,062,000)
Other	2,292,000
Stockholders' equity end of period	435,588,000
Noncontrolling Interests [Member]
Variable Interest Entity [Line Items]
Net loss	(743,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity beginning of period	770,000
Non-cash development expenses from variable interest entities	190,000
Net Loss	(743,000)
Other	0
Stockholders' equity end of period	$ 217,000

Collaboration Agreements (Details) - USD ($)	3 Months Ended
Collaboration Agreements (Details) - USD ($)	Mar. 31, 2013	Mar. 31, 2012
Collaborative arrangements [Line Items]
Contracts and grants revenue	$ 12,741,000	$ 15,954,000
Abbott Laboratories TRU016 [Member]
Collaborative arrangements [Line Items]
Revenues related to collaborative research funding	$ 1,400,000
Pfizer CD20 [Member]
Collaborative arrangements [Line Items]
Revenues related to collaborative research funding		$ 365,000

Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
Restructuring (Details) - USD ($) $ in Thousands	Mar. 31, 2013	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]
Inception to date costs incurred	$ 2,021	$ 2,785
Total expected to be incurred	2,021	2,785
Summary of activity for liabilities [Roll Forward]
Beginning balance	0	0
Expenses incurred	1,840
Amount paid	0
Other adjustments	0
Ending balance	1,840
Restructuring expenses	1,840
EPDU Restructuring Plan [Member]
Summary of activity for liabilities [Roll Forward]
Expenses incurred		2,800
Restructuring expenses		2,800
Termination benefits [Member]
Restructuring Cost and Reserve [Line Items]
Inception to date costs incurred	1,840	1,904
Total expected to be incurred	1,840	1,904
Summary of activity for liabilities [Roll Forward]
Beginning balance	0	0
Expenses incurred	1,840
Amount paid	0
Other adjustments	0
Ending balance	1,840
Restructuring expenses	1,840
Contract termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Inception to date costs incurred	0	500
Total expected to be incurred	0	500
Summary of activity for liabilities [Roll Forward]
Beginning balance	0	0
Expenses incurred	0
Amount paid	0
Other adjustments	0
Ending balance	0
Restructuring expenses	0
Other costs [Member]
Restructuring Cost and Reserve [Line Items]
Inception to date costs incurred	181	381
Total expected to be incurred	181	$ 381
Biosciences [Member]
Summary of activity for liabilities [Roll Forward]
Expenses incurred	2,000
Restructuring expenses	$ 2,000

Business Interruption Insurance Recovery (Details)	3 Months Ended
Business Interruption Insurance Recovery (Details)	Mar. 31, 2013 USD ($)
Business Interruption Insurance Recovery [Abstract]
BusinessInterruptionInsuranceRevenue	$ 835,000

Earnings per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Numerator:
Net loss	$ (8,062)	$ (6,829)
Denominator:
Weighted-average number of shares-basic (in shares)	35,968,064	36,045,839
Dilutive securities-equity awards (in shares)	0	0
Weighted-average number of shares-diluted (in shares)	35,968,064	36,045,839
Loss per share-basic (in dollars per share)	$ (0.22)	$ (0.19)
Loss per share-diluted (in dollars per share)	$ (0.22)	$ (0.19)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation (in shares)	5,000,000	4,500,000

Segment information (Details) $ in Thousands	3 Months Ended
Segment information (Details) $ in Thousands	Mar. 31, 2013 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2012 USD ($)
Segment Reporting Information [Line Items]
Number of business segments	2
Number of business units	2
External revenue	$ 43,100	$ 50,311
Research and development	30,724	26,246
Interest revenue	23	25
Interest expense	(11)	(3)
Depreciation and amortization	4,163	2,373
Net income (loss)	(8,062)	(6,829)
In-process research and development assets	41,800		$ 41,800
Goodwill	5,502		5,502
Total assets	538,385		$ 564,230
Biodefense [Member]
Segment Reporting Information [Line Items]
External revenue	42,159	48,636
Net income (loss)	4,610	14,266
Biosciences [Member]
Segment Reporting Information [Line Items]
External revenue	941	1,675
Net income (loss)	(11,372)	(19,891)
All Other [Member]
Segment Reporting Information [Line Items]
External revenue	0	0
Net income (loss)	$ (1,300)	$ (1,204)

Subsequent Events (Details) $ in Millions	3 Months Ended
Subsequent Events (Details) $ in Millions	Mar. 31, 2013 USD ($)
Subsequent Event [Line Items]
Asset Purchase Price	$ 26